Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Tactics used x Hedge Fund & MM to acquire shareholder stock

<< Previous

Bullboard Posts

Next >>

Comment by Quentin30on Dec 23, 2022 12:11pm

134 Views

Post# 35189664

RE:RE:RE:RE:RE:RE:Tactics used x Hedge Fund & MM to acquire shareholder stock

Noteable, let me clear this up for u, I DO NOT work for a hedge fund... I'm a retail investor, and one who's sick and tired of pumpers like you making this company sound like the investment of the century. It's not, it's been a cash sink since inception.

There are a ton of questions around ownership, trial length and efficacy, that neither you nor your unicorn lackies ever address.

Merry Christmas, and assuming you are right, we can all retire next year.
LOL

<< Previous

Bullboard Posts

Next >>

Soma Gold poised to extend profitable track record